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We used the Archimedes Model, a mathematical simulation model (Model) to estimate the clinical- and
cost-effectiveness of using LDL particle concentration (LDL-P) as an adjunct or alternative to LDL
cholesterol (LDL-C) to guide statin therapy. LDL-P by NMR has been shown to be a better measure of
cardiovascular disease (CVD) risk than LDL-C, and may therefore be a better gauge of the need for and
response to statin treatment. Using the Model, we conducted a virtual clinical trial comparing the use of
LDL-C alone, LDL-P alone, and LDL-C and LDL-P together to guide treatment in the general adult pop-
ulation, and in high-risk, dyslipidemic subpopulations. In the general population, the 5-year major
adverse cardiovascular event (MACE) relative risk reduction (RRR) of LDL-P alone compared to the
control arm (LDL-C alone) was 5.0% (95% CI, 4.7e5.3; p < .0001); using both LDL-C and LDL-P (dual
markers) led to 3.0% RRR compared to the control arm (95% CI, 2.8e3.3; p < .0001). For individuals with
diabetes, the RRR was 7.3% (95% CI, 6.4e8.2; p < .0001) for LDL-P alone and 6.9% for dual markers (95% CI,
6.1e7.8; both, p < .0001).
In the general population, the costs per quality-adjusted life year (QALY) associated with the use of
LDL-P alone were $76,052 at 5 years and $8913 at 20 years and $142,825 at 5 years and $25,505 at 20
years with the use of both markers. In high-risk subpopulations, the use of LDL-P alone was cost-saving
at 5 years; whereas the cost per QALY for the use of both markers was $14,250 at 5 years and $859 at 20
years for high-risk dyslipidemics, $19,192 at 5 years and $649 at 20 years for diabetics, and $9030 at 5
years and $7268 at 20 years for patients with prior CHD. In conclusion, the model estimates that using
LDL-P to guide statin therapy may reduce the risk of CVD events to a greater extent than does the use of
LDL-C alone and maybe cost-effective or cost-saving for high-risk patients.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Reducing low-density lipoprotein (LDL) levels with pharmaco-
logic agents has been associated with a marked reduction in car-
diovascular disease (CVD) events [1]. LDL cholesterol (LDL-C) has
been the historical measure of LDL quantity used to guide LDL-
lowering treatment decisions. An alternative measure of LDL: þ1 415 490 0399.
del.com, hfolse@gmail.com
m (D. Goswami), badri.
n), mbudoff@labiomed.org
Ireland Ltd. This is an open accessquantity is LDL particle number (LDL-P), determined directly by
nuclear magnetic resonance (NMR) spectroscopy [2,3]. Due to
variability in the amount of cholesterol per LDL particle, LDL-C and
LDL-P levels do not always agree (i.e., are discordant) [4e6]. For
example, if an individual patient had a low amount of cholesterol
per LDL particle, their LDL-C might appear normal even though
their LDL-P was elevated. When LDL-C and LDL-P levels agree (i.e.,
are concordant), either measure provides a good estimate of LDL-
related CVD risk [7,8]. However, when LDL-C and LDL-P are
discordant, as is common in patients with type 2 diabetes or
metabolic syndrome, risk tracks with LDL-P, not LDL-C [7e10].
These results suggest that LDL-P may provide a more reliable
target of therapy for the management of LDL-related risk in somearticle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-
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statin therapy for lowering LDL-P [11e14]. However, statins were
found to lower LDL-C more than LDL-P and, despite attainment of
LDL-C goals, many statin-treated patients have persistently
elevated LDL-P levels [12e14]. Thus, many patients who achieve
LDL-C goals have residual CVD risk that may require more aggres-
sive therapy [15e18]. In this context, the aim of this study was to
estimate the clinical- and cost-effectiveness of using LDL-P in
conjunction with or in place of LDL-C to guide statin therapy.
2. Methods
We used the Archimedes Model (Model) to perform this anal-
ysis. TheModel is able to conduct studies that would not be feasible
in the real world and to forecast long-term outcomes with a high
level of precision and accuracy [19e21].
3. The Archimedes model
The Model is a trial-validated, clinically detailed simulation
model of human physiology, disease progression, and healthcare
delivery [19e21]. The core of the Model is a set of equations rep-
resenting the physiological pathways pertinent to diseases and
their complications [19]. Use of the Model enables a comparison of
a wide range of treatments for multiple comorbidities within a
single integrated view.
The Model creates a simulated population of virtual individuals
with distributions and correlations of risk factors, behaviors,
medication usage, and medical histories reﬂective of a real popu-
lation. When simulating a clinical trial, a study cohort of patients
meeting the trial inclusion/exclusion criteria is recruited from this
simulated population. Each patient's life is then simulated for the
trial period. The Model allows interventions and protocol changes
to be compared using an identical population for each trial arm.
This design allows for the simulation of complex treatment pro-
tocols and the addition of novel diagnostics. The Model has been
validated by simulatingmore than 50major clinical trials, including
9 trials related to cardiovascular disease. [21e25]
4. Simulated study population
In this study, we simulated 1,000,000 patients reﬂective of the
general US population aged 20e84. Virtual patients were created
based on the proﬁles of patients in the National Health and
Nutrition Examination Survey (NHANES), 1999e2008 [26]. We also
examined the following embedded subpopulations: patients at
moderate and high risk of coronary heart disease (CHD) (as deﬁned
below) and patients with diabetes (fasting plasma glucose
[FPG] > 125 mg/dL) or CHD (at least 1 episode of coronary heart
failure [CHF], atrial ﬁbrillation, left ventricular hypertrophy [LVH],
or coronary artery disease [CAD], which includes MI and angina).
Only patients eligible for lipid-lowering therapy (see below) were
included in these subpopulations.
5. Risk categories and LDL goals
CHD risk categories and LDL-C goals were deﬁned according to
Adult Treatment Panel III (ATP III) guidelines [1]. Low-risk patients
were identiﬁed as those with 0e1 risk factors. ATP III guidelines
recommend managing these patients to an LDL-C goal of 160 mg/
dL. Since statin therapy is applied infrequently to such patients, we
focused this study on higher risk patients. Moderate-risk (including
moderately high-risk) patients were those with 2 or more risk
factors and a 10-year CHD risk <20%. They had an LDL-C goal of
<130 mg/dL. High-risk (including very high-risk) patients werethosewith 2 ormore risk factors and a 10-year CHD risk >20%. They
had an LDL-C goal of <100 mg/dL.
LDL-P goals were deﬁned as the percentile equivalents to the
corresponding LDL-C goals, using observed percentile values in the
Multi-Ethnic Study of Atherosclerosis (MESA) [27]. The LDL-P goals
were 1383 (68th percentile) and 1053 (30th percentile) nmol/L for
moderate- and high-risk patients, respectively.
6. LDL management protocol
The protocol for the management of LDL-C was based on ATP III
guidelines and consisted of 3 steps: (1) risk stratiﬁcation, based on
the levels of total cholesterol (TC) and high-density lipoprotein
cholesterol (HDL-C) and other risk factors, by which patients were
assigned to low-, moderate-, or high-risk categories; (2) LDL eval-
uation, in which patients whose LDL-C level was above goal were
referred to treatment; and (3) treatment, inwhich patients received
lipid-lowering therapy until their LDL-C was below goal. Risk
stratiﬁcation and evaluation occurred at each visit for all patients,
allowing their risk category to be upgraded (but not downgraded) if
their risk increased between visits. The treatment protocol for all
patients consisted initially of lifestyle modiﬁcation, and also sim-
vastatin 10mg/day if theywere high-risk or had LDL-C>220mg/dL.
The lifestyle modiﬁcation intervention was based on diet, and
wasmodeled as a 3% reduction inweight and 1.9% reduction in both
systolic and diastolic blood pressure [28]. The rate of adherence to
lifestyle modiﬁcation was assumed to be 9.5% for primary pre-
vention and 14% for patients with CAD, based on calibration to
prevalence as observed in NHANES, 2007e2008 [29,30]. In-
dividuals who received only lifestyle modiﬁcation at trial start were
followed-up at 3 months and assigned simvastatin 10 mg/day if
their LDL-C was above goal. After starting simvastatin, patients
were followed-up after 6 weeks and then every 4e6 months, as
recommended by guidelines [1]. If their LDL-C was still above goal,
theywere given intensiﬁcation of simvastatin to 20mg, then 40mg,
and ultimately atorvastatin 80 mg. Patients who still did not reach
goal were not given additional drugs/therapy. Patients with LDL-C
values below goal or who were receiving a statin at the
maximum dose returned only for annual visits. This protocol, in
which all patients start lowand titrate upwards, is an idealization of
actual practice, in which many patients start on simvastatin 20 or
40 mg, but do not increase their dose even if their LDL-C remains
above goal [23].
7. Simulated trial design
Patients received care according to all standard care protocols,
including measurements of body mass index (BMI) annually, FPG
every 3 years, and LDL-C every 1e3 years, in order to diagnose cases
of obesity, diabetes, or dyslipidemia, respectively. BMI, FPG, and
LDL-C/LDL-P were also measured for diagnostic purposes at the
start of the trial. Patients could also be diagnosed with and treated
for CHD based on symptoms both before and during the trial.
Patientswereplaced into 3 trial arms titled: Control, LDL-PAlone,
and LDL-C and LDL-P (henceforth called the Dual arm). In all three
arms, the titration sequence was the same as described above (i.e.
simvastatin 10, 20, 40 mg and atorvastatin 80 mg), but the arms
differed as to whether treatment was to targets of LDL-C, LDL-P, or
both. In the Control arm, treatment was given in accordance with
LDL-C goals only. In the LDL-P Alone arm, the only measure of LDL
used was LDL-P. Therefore, patients received an LDL-P by NMR test
to determine LDL-P levels, and were referred to statin treatment or
received increases in dosage only if their LDL-P was above goal. In
this arm, the ﬁnal statin dose could be higher or lower than in
Control for the samepatient proﬁle. Apatientwithdiscordantlyhigh
Table 1
Cost and health disutility assumptions.
Event or treatment Cost Source
Full lipid panel $18.05 Medicare physicians
fee schedule (33)
LDL-P NMR $42.29 Medicare physicians
fee schedule (33)
Statins $4.00/mo Healthwarehouse.com (32)
MI $23,653.34 Medicare LDS (34)
Stable angina $9944.49 Medicare LDS (34)
Unstable angina $18,435.37 Medicare LDS (34)
Stroke $11,402.49 - $105,735.60 Samsa (35)
CHF initial cost $9809.58 Esposito (36)
CHF continuing cost $8800.14/yr Esposito (36)
Atrial Fibrillation $23,528.43/yr Wu (37)
Condition Disutility
Hypertension 0.025 Sullivan (38)
Diabetes 0.0351 Sullivan (38)
MI 0.0409 Sullivan (38)
Angina 0.0412 Sullivan (38)
Stroke 0.046 Sullivan (38)
CHF 0.063 Sullivan (38)
Num. Chron. Cond. Disutility
1 0.0942 Sullivan (38)
2 0.0876 Sullivan (38)
3 0.0711 Sullivan (38)
4 0.0547 Sullivan (38)
5 0.0419 Sullivan (38)
6 0.0035 Sullivan (38)
7 0.0344 Sullivan (38)
8 0.0026 Sullivan (38)
9 0.0097 Sullivan (38)
10 0.0942 Sullivan (38)
LDL-P NMR ¼ low-density lipoprotein particle concentration by nuclear magnetic
resonance; MI¼myocardial infarction; CHF¼ congestive heart failure; Num. Chron.
Cond. ¼ number of chronic conditions.
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Control, while a patient with discordantly low LDL-P might be
titrated to a lower dose, depending on the particular patient's evo-
lution. In the Dual arm, evaluationwas based solely on LDL-C levels.
If treatment was indicated, an LDL-P test was done and both LDL-C
and LDL-P goals were used for management, with patients
increasing their statin dose if either their LDL-C or their LDL-P was
above goal. In the Dual arm, the statin dose was always at least as
high as would be given to patients in the Control armwith the same
LDL-C value, but a patient with discordantly high LDL-P might be
titrated to a higher statin dose than in Control. Of note, in the LDL-P
Alone arm, LDL-P information is used for both LDL evaluation and
treatment, whereas in the Dual Arm, LDL-P information is used only
when a patient has been referred to treatment based on having LDL-
C above goal. This resulted in more patients being referred to
treatment or having their risk category upgraded than in the Control
and Dual arms. All 1,000,000 patients were run through each of 3
arms, in order to reduce random noise between arms.
8. Clinical outcomes
The primary outcomes were Major Adverse Cardiovascular
Events (MACE) and CVD death. MACE included fatal and nonfatal
MI, fatal and nonfatal stroke, and CVD death. CVD death included
death due to CHD and stroke. All clinical outcomes are expressed as
relative risk reductions (RRR), absolute number of events averted
per 100,000 patients, and number needed to treat (NNT) [31]
compared to events in the Control arm.
9. Economic outcomes and assumptions
Economic outcomes reported were cost per quality-adjusted
life-year (QALY) saved. Costs for statins were obtained from
healthwarehouse.com as of July, 2013 [32]. The costs for the lipid
panel and LDL-P NMR test were $18.05 and $42.29, respectively,
based on Medicare pricing [33]. Other costs were also based on
Medicare [33,34] or, when Medicare costs were not applicable, on
the most recent available data in the literature [35e37] and were
updated to 2012 dollars. Costs for stroke and CHF include both an
initial cost as well as a continuing cost accrued over time (for up to
two years for stroke and indeﬁnitely until death for CHF). QALYs
were calculated based on the time individuals spent with different
disorders using published disutilities based on ameta-analysis [38].
The base value is 1, which represents perfect health, and the
disutility of each condition that a patient has at a given time is
subtracted from this value. There was an additional correction for
patients with multiple chronic conditions [38]. The cost and
disutility assumptions are summarized in Table 1. All costs and
QALYs were discounted at a rate of 3% per year.
10. LDL-P model
Because the source dataset for constructing the virtual popula-
tion did not include measurements of LDL-P, it was necessary to
impute LDL-P values for each patient from otherwise available
biomarkers, including LDL-C, HDL-C, TG, FPG, and BMI. We used the
MESA dataset to build the LDL-P model [27]. In this dataset, LDL-P
was measured using the NMR LipoProﬁle® test.
11. Results
The baseline characteristics for the full simulated population
and subpopulations are shown in Table 2. At baseline, average age
was 46 years, mean LDL-C was 111 mg/dL, and mean LDL-P was
1193 nmol/L. The prevalence of various diagnosed conditions was10% with moderate-risk dyslipidemia, 12% with high-risk dyslipi-
demia, 10% with diabetes and 7% with CHD.
12. Clinical outcomes
In the general population, statin therapy guided by LDL-P alone
was associated with a 5-year MACE RRR of 5.0% (95% CI: 4.7%, 5.3%)
and a 5-year CVD death RRR of 6.5% (95% CI: 5.8%, 7.3%),whereas
statin therapy guided by both LDL-C and LDL-P was associated with
a 5-year MACE RRR of 3.0% (95% CI: 2.8%, 3.3%) and a 5-year CVD
death RRR of 4.0% (95% CI: 3.5%, 4.6%) (Table 3). In absolute terms,
the numbers of events averted per 100,000 patients associated
with LDL-P alone at 5-years were 136 (95% CI: 91, 180) (NNT of 738
[95% CI: 555, 1101]) for MACE and 41 (95% CI: 19, 62) (NNT of 2468
[95% CI: 1,610, 5286]) for CVD death, and the numbers associated
with Dual goals at 5-years were 82 (95% CI: 37, 127) (NNT of 1221
[95% CI: 788, 2705]) for MACE and 25 (95% CI: 3, 47) (NNT of 4033
[95% CI: 2,149, 32,702]) for CVD death (Tables 4 and 5). When
interpreting these values, one must be aware that the Control arm
used for comparison is an active treatment arm in accordance with
ATP III guidelines.
Among the subpopulations, patients with diabetes experienced
the greatest RRR in MACE (7.3% [95% CI: 6.4%, 8.2%] for LDL-P alone
and 6.9% [95% CI: 6.1%, 7.8%] for dual goals) (Table 3). Patients with
CHD experienced the greatest RRR in CVD death (9.1% [7.4%, 10.8%]
for LDL-P alone and 8.6% [7.0%,10.2%] for dual goals) (Table 3). There
was a linear relationship between RRR and the degree of discor-
dance, deﬁned as the difference between LDL-C and LDL-P per-
centiles (R2 ¼ 0.973e0.998 for MACE, Fig. 1, and R2 ¼ 0.798e0.816
for CVD death, Fig. 2). This indicates that subpopulations with a
greater degree of discordance experienced a greater beneﬁt from
using LDL-P to guide treatment. In absolute terms, the degree of
Table 2
Baseline population characteristics.
Characteristic All MR Dyslipidemiaa HR Dyslipidemiaa Diabetesb CHDb
N 1,000,000 98,635 122,148 72,372 51,668
Age (years) 46 (15.9) 55 (13.6) 62 (12.5) 61 (11.9) 64 (12.6)
Men (%) 48 66 55 49 56
BMI (kg/m2) 28 (6.4) 29 (5.2) 32 (7.2) 35 (7.2) 30 (6.1)
Blood Pressure (mmHg)
Systolic 122 (15.8) 130 (16.3) 127 (17) 125 (14.2) 126 (16.8)
Diastolic 72 (11.4) 74 (12.4) 70 (12.1) 70 (11.8) 68 (11.9)
Cholesterol (mg/dL)
TC 192 (35.9) 198 (25.6) 171 (23.4) 175 (25.6) 174 (27.3)
LDL-C 111 (30.1) 121 (20.1) 89 (15.4) 90 (18.1) 93 (20.6)
HDL-C 54 (16.7) 45 (10.8) 51 (15) 52 (13.8) 51 (15)
Triglycerides 136 (100.9) 161 (90.1) 156 (91.3) 166 (89.8) 148 (86.9)
Fasting plasma glucose 101 (32.1) 100 (23.6) 141 (53.6) 166 (36.6) 121 (48.3)
HbA1c (%) 5.4 (0.9) 5.4 (0.7) 6.5 (1.3) 7.1 (1) 5.9 (1.2)
LDL-P 1193 (334.5) 1354 (294.9) 1062 (257.3) 1091 (269.9) 1081 (270.7)
Medical History (%)
No Dyslipidemia 70 0 0 0 0
Low-Risk Dyslipidemiaa 8 0 0 2 2
Moderate-Risk Dyslipidemiaa 10 100 0 5 11
High-Risk Dyslipidemiaa 12 0 100 93 86
Discordantly High LDL-Pc 25 31 45 47 41
Concordant LDL-Pc 49 48 45 44 46
Discordantly Low LDL-Pc 26 21 10 9 13
Obesity 31 36 54 74 41
Diagnosed diabetes 10 4 58 100 28
CHD 7 6 37 20 100
CKD 4 4 20 31 15
Current smoker 24 39 19 14 19
Hypertension 24 49 56 65 46
MI 2 1 15 8 37
Stroke 2 1 12 5 6
Subpopulations (excluding All) include only patients eligible for LDL-lowering therapy. Values are means, except where indicated as percents of the population. BMI ¼ body
mass index; TC ¼ total cholesterol; LDL ¼ low density lipoprotein; HDL ¼ high-density lipoprotein; LDL-C ¼ LDL cholesterol; LDL-P ¼ LDL particles; CHD ¼ coronary heart
disease; CKD ¼ chronic kidney disease; MI ¼ myocardial infarction; MR ¼ moderate-risk; HR ¼ high-risk.
a Dyslipidemia categories deﬁned according to Adult Treatment Panel (ATP III) guidelines [1].
b The diabetic and CHD subpopulations include only patients who also have dyslipidemia.
c Discordance deﬁned as high if 12%, low if  -12%, and concordant otherwise.
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with discordance. Patients with CHD, who have the highest base-
line risk, received the greatest absolute beneﬁt; the numbers of
MACE averted per 100,000 patients at 5-years were 463 (95% CI:
209, 716) (NNT of 144 [95% CI: 93, 320]) for LDL-P alone and 441
(95% CI: 187, 695) (NNT of 154 [95% CI: 97, 374]) for dual goals
(Tables 4 and 5). The reduction in number of events was also greater
at longer time horizons, indicating that the beneﬁt of treating to
LDL-P targets accrues gradually over time, as is to be expected for a
preventative measure.Table 3
Mean (95% conﬁdence interval) relative risk reduction of MACE and CVD death at 5, 10,
MACE LDL-P arm
Subpopulation 5 Year 10 Year 20 Year
All 5.03 (5.34;4.72) 4.75 (4.97;4.53) 3.93 (4.08;
Moderate-risk 5.38 (6.27;4.49) 5.66 (6.30;5.02) 5.35 (5.79;
High-risk 6.69 (7.30;6.07) 7.05 (7.52;6.58) 6.13 (6.46;
Diabetes 7.27 (8.19;6.35) 7.88 (8.56;7.20) 6.86 (7.33;
CHD 6.60 (7.40;5.79) 6.46 (7.07;5.85) 5.25 (5.70;
CVD death LDL-P arm
All 6.54 (7.32;5.77) 6.26 (6.79;5.74) 5.37 (5.71;
Moderate-risk 7.10 (9.48;4.71) 7.13 (8.76;5.50) 7.25 (8.34;
High-risk 8.06 (9.41;6.72) 8.51 (9.45;7.56) 7.44 (8.08;
Diabetes 8.78 (10.82;6.74) 9.06 (10.45;7.67) 8.66 (9.62;
CHD 9.08 (10.79;7.38) 8.21 (9.39;7.04) 6.76 (7.59;13. LDL reductions
For patient subpopulations with elevated LDL-C at baseline,
statin therapy guided by both LDL-P alone and Dual goals resulted
in reductions in LDL-C that signiﬁcantly exceeded those guided by
LDL-C alone (Table 6), mainly because of the use of higher doses of
statins to achieve LDL-P goals in high-risk patients. Like the MACE
RRR's, the percent change in both LDL-C and LDL-P trackedwith the
degree of discordance, and the largest reduction relative to Control
was seen in those with diabetes.and 20 years, for the Dual and LDL-P arms, relative to control.
Dual arm
5 Year 10 Year 20 Year
3.79) 3.04 (3.26;2.82) 3.30 (3.46;3.14) 2.98 (3.08;2.87)
4.91) 3.86 (4.52;3.20) 4.52 (5.01;4.03) 4.21 (4.54;-3.88)
5.80) 6.68 (7.29;6.08) 7.17 (7.63;6.71) 6.35 (6.68;6.03)
6.39) 6.93 (7.80;6.05) 7.51 (8.15;6.87) 6.82 (7.27;6.38)
4.80) 6.18 (6.93;5.42) 6.18 (6.76;5.60) 5.17 (5.60;4.75)
Dual arm
5.03) 4.00 (4.56;3.45) 4.35 (4.74;3.97) 4.04 (4.28;3.80)
6.16) 2.93 (4.33;1.54) 4.06 (5.14;2.98) 5.24 (5.99;4.49)
6.80) 8.19 (9.50;6.87) 8.56 (9.49;7.63) 7.73 (8.36;7.10)
7.71) 7.79 (9.66;5.93) 8.29 (9.58;7.00) 8.31 (9.21;7.41)
5.93) 8.58 (10.16;7.00) 7.86 (8.96;6.76) 6.60 (7.37;5.83)
Table 4
Mean (95% conﬁdence interval) absolute reduction in number of events per 100,000 patients of MACE and CVD death at 5,10, and 20 years, for the Dual and LDL-P arms, relative
to control.
MACE LDL-P arm Dual arm
Subpopulation 5 Year 10 Year 20 Year 5 Year 10 Year 20 Year
All 136 (91; 180) 275 (210; 341) 525 (427; 624) 82 (37; 127) 191 (126; 257) 397 (298; 496)
Moderate-risk 497 (287; 707) 1049 (754; 1344) 1876 (1450; 2301) 496 (286; 706) 1066 (772; 1361) 1944 (1519; 2370)
High-risk 215 (42; 389) 502 (245; 758) 1123 (729; 1517) 155 (20; 329) 400 (143; 658) 884 (489; 1278)
Diabetes 693 (312; 1075) 1235 (724; 1745) 1865 (1158; 2572) 649 (267; 1030) 1182 (671; 1692) 1838 (1131; 2545)
CHD 463 (209; 716) 1072 (703; 1440) 2039 (1491; 2587) 441 (187; 695) 1022 (653; 1390) 2029 (1481; 2577)
CVD death LDL-P arm Dual arm
All 41 (19; 62) 91 (58; 125) 209 (153; 266) 25 (3; 47) 63 (30; 97) 157 (101; 214)
Moderate-risk 174 (58; 290) 412 (234; 589) 884 (584; 1185) 177 (61; 293) 415 (237; 592) 918 (618; 1219)
High-risk 56 (22; 134) 138 (14; 262) 420 (193; 647) 23 (56; 102) 78 (47; 203) 303 (76; 531)
Diabetes 338 (104; 572) 630 (285; 975) 1127 (573; 1680) 319 (85; 553) 603 (258; 948) 1100 (546; 1654)
CHD 159 (21; 298) 386 (170; 603) 959 (582; 1337) 142 (3; 280) 353 (136; 571) 921 (543; 1298)
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In the full study population, statin therapy guided by LDL-P
alone had a cost per QALY of $76,052 at 5 years and $8913 at 20
years (Table 7). Statin therapy guided by dual goals had a cost per
QALY of $142,825 at 5 years and $25,505 at 20 years (Table 7). Costs
per QALY were much lower in the high-risk subpopulations. Statin
therapy guided by LDL-P alone was cost-saving at 5 years in pa-
tients with high-risk dyslipidemia, diabetes and CHD. The 5-year
cost per QALY of statin therapy guided by dual goals was $14,250
for high-risk dyslipidemic patients, $19,192 for patients with dia-
betes and $9030 for patients with CHD.
15. Discussion
This simulation study examined the relative effectiveness of
statin therapy guided by LDL-P levels compared to statin therapy
guided by LDL-C levels in reducing the incidence of CVD events. The
Model estimated that treating patients to LDL-P goals, either in
conjunction with or in place of LDL-C goals, would be substantially
more effective in reducing MACE and CVD death risk than treat-
ment to LDL-C goals alone; especially in patients with high risk as
deﬁned by ATP III guidelines, diabetes, or prior CHD.
In addition, the Model was used to estimate the relative cost-
effectiveness of using the two measures to guide statin therapy. If
one assumes a cost-effectiveness threshold of $50,000 per QALY
gained, then in the general population the use of Dual LDL-P and
LDL-C goals was cost-effective only at 20 years whereas the use of
LDL-P goals alonewas cost-effective at 10 and 20 years. However, in
patients with diabetes or at high risk for CHD, management to Dual
goals was cost-effective while management to LDL-P goals aloneTable 5
Mean (95% conﬁdence interval) number needed to test (NNT) to prevent one occurrence o
control.
MACE LDL-P arm
Subpopulation 5 Year 10 Year 20 Year
All 738 (555; 1101) 363 (293; 476) 190 (160; 2
Moderate-risk 464 (257; 2387) 199 (132; 409) 89 (66; 13
High-risk 201 (142; 349) 95 (74; 133) 53 (43; 69
Diabetes 216 (140; 478) 93 (69; 142) 49 (39; 67
CHD 144 (93; 320) 81 (57; 138) 54 (39; 86
CVD death LDL-P arm
All 2468 (1610; 5286) 1095 (801; 1729) 477 (376; 6
Moderate-risk 1794 (749;-4535) 727 (382; 7367) 238 (155; 5
High-risk 574 (345; 1718) 243 (170; 427) 113 (84; 17
Diabetes 627 (336; 4678) 259 (166; 590) 104 (75; 17
CHD 296 (175; 960) 159 (103; 351) 89 (60; 17was cost-saving at 5, 10, and 20 years. In high risk patients with
prior CHD, the use of LDL-P goals alone was cost-saving only at 5
years but not at 10 and 20 years since most of the savings are due to
the prevention of recurrent MI events shortly after the previous MI,
and the risk of recurrent MI wanes with time.
The relative risk reductions in MACE and CVD death observed in
the LDL-P Alone arm were at least as great as in the Dual arm in all
subpopulations, and were signiﬁcantly higher in the general pop-
ulation and in patients with moderate-risk dyslipidemia. This
advantage is due to the use of LDL-P information at an earlier step
in the treatment protocol. Moreover, the LDL-P alone arm was
considerably more cost-effective, due to the facts that a standard
lipid panel test measuring LDL-C is not performed and that statin
treatments are targeted more selectively to those patients most
likely to beneﬁt (i.e. those with discordantly high LDL-P).
Using LDL-P information in addition to LDL-C to manage LDL-
related CVD risk represents a minimal departure from standard
care, and is conservative in the sense that since the recommended
LDL-C goals are maintained, at a minimum, patients receive the
same treatment as they would in the Control arm. The use of LDL-P
alone for both evaluation and treatment represents a greater de-
parture from standard care, in that no LDL-C information is used to
guide treatment decisions, only LDL-P. Patients with high LDL-P
levels receive more aggressive therapy, regardless of their LDL-C
level, whereas patients with low LDL-P levels receive lower doses
of statin, even if their LDL-C level is discordantly high. For these
patients, using LDL-P alone reduces unnecessary treatment. Since,
in the setting of discordance, CVD risk tracks with LDL-P and not
with LDL-C [7,9], these patients have a lower risk than would be
determined based on LDL-C levels and thus do not require
aggressive statin therapy.f MACE and CVD death at 5, 10, and 20 years, for the Dual and LDL-P arms, relative to
Dual arm
5 Year 10 Year 20 Year
34) 1221 (788; 2705) 522 (389; 795) 252 (201; 335)
7) 647 (304;-5117) 250 (152; 700) 113 (78; 205)
) 202 (142; 349) 94 (73; 130) 51 (42; 66)
) 227 (144; 534) 98 (72; 153) 49 (39; 68)
) 154 (97; 374) 85 (59; 149) 54 (39; 88)
Dual arm
53) 4033 (2149; 32702) 1576 (1030; 3352) 635 (467; 991)
17) 4343 (984;1799) 1277 (492;2142) 330 (188; 1320)
1) 566 (342; 1642) 241 (169; 422) 109 (82; 162)
2) 706 (357; 32211) 283 (175; 734) 109 (77; 184)
4) 313 (181; 1175) 166 (105; 388) 91 (60; 183)
Fig. 1. Mean discordance versus 5-year MACE RRR e Subpopulations with higher
discordance have greater risk reduction.
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particle number in the management of at-risk patients [39e43].
The American Association of Clinical Endocrinologists (AACE) [39],
the National Lipid Association (NLA) [40], the American Diabetes
Association (ADA) in conjunction with the American College of
Cardiology (ACC) [41], and the American Association for Clinical
Chemistry (AACC) [42,43] have all developed consensus position
statements on lipoprotein particle management in individuals at
risk for CVD. The 2013 AACE consensus statement cites expert
opinion that LDL-P “must be recognized and included in treatment
recommendations” for patients with type 2 diabetes, insulin
resistance, metabolic syndrome, and/or hypertriglyceridemia who
often have persistently elevated LDL-P, even when LDL-C and non-
HDL-C are at goal levels (p. 23) [39].
The results of this analysis show a strong link between CVD risk
and the degree of LDL discordance. The greater the discordance, the
more effective it was to treat to LDL-P goals (Figs. 1 and 2). Further,
the economic analyses showed much lower costs per QALY gained
for subpopulations with high discordance. Our model of LDL-P
estimates that patients with high BMI, TG, and FPG, and low HDL
are more likely to have higher discordance (see supplemental
material). This set of characteristics is commonly observed in pa-
tients with diabetes. Thus, of the subpopulations considered, the
model estimated the highest level of discordance, the greatest
relative risk reduction, and the greatest cost-effectiveness for the
diabetic subpopulation.Fig. 2. Mean discordance versus 5-year CVD death RRR e Subpopulations with higher
discordance have greater risk reduction.16. Limitations
There are several limitations of this study. First, it is based on a
mathematical simulation model and is subject to the assumptions
used to create the Model. However, the Model has been found to be
very accurate in numerous validation studies [21e23]. Some of the
data sources used to parameterize the Model consist primarily of
Caucasian persons, so the results may not be as generalizable to
non-white populations. Costs for events are based on Medicare
costs and may underestimate the actual costs for a non-Medicare
population. However, Medicare costs represent a relatively objec-
tive standard and are routinely used in cost effectiveness studies.
Also, event-related costs were represented in 2012 dollars, whereas
costs for tests and medications are in 2013 dollars. However,
updating the cost assumptions by one or two years would be very
unlikely to change materially our results, particularly the relative
beneﬁt of LDL-P testing and its use in lipid management. Further-
more, if the costs associated with events have been under-
estimated, then the simulation results represent a conservative
assumption because higher costs for events would make the
intervention (i.e. LDL-P testing) appear more cost-effective.
The analysis assumed 100% adherence to statin therapy, with no
statin intolerance (which would necessitate changing dose or
coming off therapy) in order to approximate a per-protocol or on-
treatment analysis. While this is not typically observed in clinical
practice, the aim of this analysis was to estimate the impact of using
LDL-P information to guide patientswho adhere to statin treatment.
For many patients, the use of LDL-P information led to more
aggressive statin therapy in order to reach goal. The inclusion of
adverse effects in the model would be expected to reduce the
observed beneﬁt. Furthermore, themodel assumes that the effect of
treatment is constant for the duration of the model, even though in
reality treatment effects are likely not constant over long durations,
possiblydue toeitherwaningadherenceorwaningefﬁcacy.Wehave
greater conﬁdence in the results for the 0e5 year time horizon
because the majority of trial data used to parameterize the treat-
mentmodel was generated on this time scale. Although longer time
scales may introduce greater uncertainty, it is often useful to model
the cost-effectiveness of an intervention over longer time horizons.
Another important limitation is the absence of data on
measured LDL-P in the dataset used to model this virtual popula-
tion, which necessitated the imputation of LDL-P from other bio-
markers. We demonstrated that LDL-P could be imputed using, in
order of signiﬁcance, LDL-C, HDL-C, TG, FPG, and BMI. While at the
population level the distribution of imputed LDL-P was a very close
ﬁt to the data, at the individual level, our model of LDL-P was
slightly biased in that it overestimated LDL-P for individuals with
low LDL-P and underestimated LDL-P for patients with high LDL-P
(see Appendix). Hence, our imputed LDL-P was less discriminating
than actual LDL-P. This is indicative of the fact that LDL-P is truly an
independent risk factor. If measured LDL-P levels better predict
CVD events than imputed LDL-P levels, then the actual beneﬁt of
treating to LDL-P targets will be greater than that estimated by the
Model.
This study compared LDL-C and LDL-P but did not estimate the
effectiveness of other alternate measures of LDL-related risk, such
as apolipoprotein B (apo B) or non-HDL-C. Apo B is associated with
a number of lipoprotein particles, including LDL, and thus can be
used to estimate the number of LDL particles, but it is less speciﬁc
than LDL-P by NMR [43]. Although non-HDL-C provides a more
accurate measure of the risk of CVD events than LDL-C, both LDL-P
by NMR and apo B have been shown to be superior to non-HDL-C,
particularly in the setting of discordance caused by variations in the
amount of cholesterol per lipoprotein particle [10,44]. Considering
that all three measures of LDL-related risk outperform LDL-C as a
Table 6
Mean (95% CI) percent change in LDL-C and LDL-P for subpopulations with elevated LDL-C at baseline.
LDL-C reduction (%) LDLP arm Dual arm
Subpopulation Year 5 Year 10 Year 20 Year 5 Year 10 Year 20
Moderate-risk 4.81 (4.97, 4.65) 4.34 (4.5, 4.18) 4.8 (4.97, 4.63) 4.96 (5.11, 4.81) 4.6 (4.75, 4.44) 4.36 (4.52, 4.2)
High-risk 6.96 (7.12, 6.8) 7.03 (7.18, 6.87) 7.27 (7.44, 7.11) 7.29 (7.44, 7.13) 7.54 (7.7, 7.37) 8.1 (8.26, 7.93)
Diabetes 7.63 (7.79, 7.47) 7.63 (7.78, 7.47) 7.81 (7.97, 7.65) 7.64 (7.8, 7.48) 7.83 (7.99, 7.67) 8.34 (8.51, 8.18)
CHD 6.06 (6.25, 5.88) 6.16 (6.34, 5.99) 6.19 (6.37, 6) 6.24 (6.43, 6.05) 6.54 (6.72, 6.37) 6.95 (7.13, 6.78)
LDL-P reduction (%) LDLP arm Dual arm
Moderate-risk 4.76 (4.92, 4.59) 4.4 (4.58, 4.23) 4.65 (4.83, 4.47) 4.59 (4.76, 4.42) 4.19 (4.37, 4.02) 3.83 (4.01, 3.64)
High-risk 6.38 (6.57, 6.2) 6.39 (6.57, 6.2) 6.49 (6.68, 6.3) 6.57 (6.75, 6.39) 6.69 (6.88, 6.5) 6.99 (7.18, 6.8)
Diabetes 6.96 (7.14, 6.79) 6.91 (7.09, 6.73) 6.91 (7.09, 6.74) 6.86 (7.05, 6.68) 6.95 (7.13, 6.77) 7.2 (7.38, 7.01)
CHD 5.58 (5.77, 5.39) 5.56 (5.75, 5.37) 5.52 (5.71, 5.33) 5.6 (5.79, 5.4) 5.7 (5.88, 5.52) 5.94 (6.13, 5.75)
H.J. Folse et al. / Atherosclerosis 236 (2014) 154e161160predictor of CVD events in epidemiological studies, one would
expect that, similar to LDL-P, the use of apo B or non-HDL-C to guide
statin therapy in the Model would also reduce the risk of CVD
events to a greater extent than the use of LDL-C alone.
The treatment protocols of this study were based on ATP III
guidelines, which recommended treatment to speciﬁc risk-based
LDL-C targets [1]. Since this analysis was performed, new guide-
lines were issued by the American College of Cardiology (ACC) and
the American Heart Association (AHA) [45], which emphasize use
of statin therapy in groups demonstrating cardiovascular risk
reduction in randomized controlled trials. Due to exclusive reliance
on RCT data, this guideline made no recommendation for or against
use of speciﬁc LDL targets in managing patients to prevent car-
diovascular events. Importantly, the new guideline does advise LDL
testing after instituting therapy to monitor individual response,
patient adherence, and to guide clinical judgment regarding
adjustment of medications to achieve an improved individual
response. By contrast, international guidelines, including the 2013
International Atherosclerosis Society (IAS) position paper on rec-
ommendations for the management of dyslipidemia, continue to
endorse LDL targets, basing their position on evidence from
epidemiological studies and genetic studies as well as RCT's [46].
The primary objective of our study was not to evaluate out-
comes related to speciﬁc LDL-P targets, but rather to compare the
effectiveness of using LDL-P (alone or in conjunctionwith LDL-C) to
using LDL-C alone to monitor patients on statin therapy. Our study
suggests the use of LDL-P to evaluate andmonitor high risk patients
with dyslipidemia has the potential to reduce rates of CVD events
and mortality and to be cost-saving to cost-effective at 5 years.
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